Navigation Links
MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
Date:8/19/2007

diabetes mellitus within

4-12 months of diagnosis

Pancreatic Led by Dr. Bernhard http://www.clinicaltrials.gov

islet cell Hering of the University (search for NCT00265473)

transplantation of Minnesota, this Phase

with teplizumab 2 trial funded by NIDDK

induction is enrolling patients

therapy less than 40 years old

who have been insulin

dependent for more

than 5 years

About Teplizumab

Teplizumab, also called MGA031 and hOKT3-gamma-1 (Ala-Ala), is a humanized monoclonal antibody engineered to alter the function of the T lymphocytes that mediate the destruction of the insulin-producing beta cells of the islets of the pancreas. Teplizumab binds to an epitope of the CD3-epsilon chain expressed on mature T cells and by doing so, may modulate the immunologic response that causes disease.

About Type 1 Diabetes

Type 1 diabetes is an autoimmune disease in which the body's immune system attacks and destroys the insulin-producing beta cells of the pancreas. The symptoms associated with type 1 diabetes can appear suddenly and leave a person dependent on injected insulin for life. The disease carries the constant threat of devastating complications such as heart and kidney disease, nerve damage and blindness. Although diagnosis most often occurs in childhood and adolescence, the disease can strike adults as well. Individuals with type 1 diabetes must test their blood sugar four or more times per day and take multiple insulin injections daily or continually infuse insulin through a pump. While trying to balance insulin doses with their food intake and daily activities, people with this form of diabetes must always be prepared for serious hypoglycemic (low blood sugar) and hyperglycemic (high blood sugar) reactions, both
'/>"/>

SOURCE MacroGenics, Inc.

Copyright©2007 PR Newswire.

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. New Study Reveals Limitations of a Complex and Challenging Global Tuberculosis Drug Marketplace
4. Global Rabies Treatment May be Possible with NanoViricides Drugs
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... GLENWOOD, Ill. , May 20, 2013 ... leader in personal and environmental radiation measurement and monitoring, ... accessories, announced today that its Board of Directors declared, ... quarterly cash dividend of $0.55 per share for the ... paid on July 3, 2013, to shareholders of record ...
(Date:5/20/2013)... , May 20, 2013   National Community ... Hoey , RPh, MBA issued the following statement ... Associates regarding Medicare Part D "preferred pharmacy" drug ... offering patients the plan,s lowest advertised co-payments: ... Medicare and MedPAC , 16 ...
(Date:5/20/2013)...  TRACE International today released its Global Enforcement ... against individuals and government or business entities for bribery ... 2012 is the third in an annual series ... "Although the number of outbound enforcement actions fell ... priority," said Alexandra Wrage , TRACE ...
Breaking Medicine Technology:Landauer, Inc. Declares Regular Cash Dividend 2Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 2Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 3Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 4TRACE Releases 2012 Global Enforcement Report 2TRACE Releases 2012 Global Enforcement Report 3
... Elsevier, the world-leading publisher of ... announced today that its 2012 eBook Frontlist collections ... Elsevier,s online platform for scientific content. This release ... depth of the eBook collection on SciVerse ScienceDirect. ...
... 2011 Baxa Corporation , a leading provider ... has released a software upgrade for its ExactaMix® ... 14 updates that provide Directors of Pharmacy with enhanced ... worldwide use ExactaMix 2400 (EM2400) and ExactaMix 1200 (EM1200) ...
Cached Medicine Technology:Elsevier Announces New 2012 Frontlist eBooks Collection on SciVerse ScienceDirect Available for Advance Purchase 2Elsevier Announces New 2012 Frontlist eBooks Collection on SciVerse ScienceDirect Available for Advance Purchase 3Baxa Corporation Bolsters Patient Safety With ExactaMix® Compounder Software Upgrade 2Baxa Corporation Bolsters Patient Safety With ExactaMix® Compounder Software Upgrade 3Baxa Corporation Bolsters Patient Safety With ExactaMix® Compounder Software Upgrade 4
(Date:5/21/2013)... 2013, PHILADELPHIA ─ The negative effects of poorly ... performance in urban schoolchildren has been confirmed in ... been recognized that missed sleep and school absences ... our study is the first to explore the ... in real time, prospectively, using both objective ...
(Date:5/21/2013)... physical activity appears to be an independent predictor ... pulmonary disease (COPD) will end up being hospitalized, ... in Connecticut. The study also corroborates an earlier ... an increased incidence of hospitalizations among patients with ... be presented at the ATS 2013 International Conference. ...
(Date:5/21/2013)... 2013, PHILADELPHIA ─ A novel approach to obstructing ... of asthma has shown promise in a Phase ... , Their research will be presented at the ... simultaneously online in the New England Journal ... trial tested the efficacy and safety of the ...
(Date:5/21/2013)... PHILADELPHIA─Treatment with an Alpha-1 proteinase inhibitor (A1-PI), a ... breakdown and protects the lung,s elasticity, is effective ... with Alpha-1 antitrypsin deficiency (AATD), a life-threatening genetic ... the 2013 American Thoracic Society International Conference. , ... the loss of lung tissue as measured by ...
(Date:5/21/2013)... After the success of its inaugural 1,000 lb. ... Body Boot Camp Goderich will be hosting its 2nd Annual ... Goderich fitness center located at 199 Anglesea Street Goderich, ... goal is to inspire and motivate local community residents to ... The fee to participate is discounted to $40 for the ...
Breaking Medicine News(10 mins):Health News:Asthma symptoms impair sleep quality and school performance in children 2Health News:Exercise levels may predict hospitalizations in COPD population 2Health News:Monoclonal antibody appears effective and safe in asthma Phase IIa trial 2Health News:Monoclonal antibody appears effective and safe in asthma Phase IIa trial 3Health News:Treatment with A1-PI slows the progression of emphysema in Alpha-1 antitrypsin deficiency 2Health News:Treatment with A1-PI slows the progression of emphysema in Alpha-1 antitrypsin deficiency 3Health News:Goderich Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 2Health News:Goderich Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 3
... of Public Health reported that most of the flu shot ... to the department, 94% of the state's total order has ... 24. Over 1.7 million vaccines will be stocked that includes ... Centers for Disease Control and Prevention revealed that this flu ...
... The World Health Organization (WHO), on Friday, had initiated the ... prevent infections associated //with Health care practices. WHO said that ... costs but also will save lives. ,It is ... by the infections caused by the hospitals, which are mainly ...
... are more likely to develop certain types of cancer ... // ,Grace LeMasters and colleagues at the ... fire fighters from 32 previously published scientific studies to ... of their profession, reported science portal EurekAlert. ...
... recent study revealed that consuming just two cups of green ... Texas in collaboration with their counterparts in the UK carried ... online edition of the Journal of Allergy and Clinical Immunology. ... (EGCG) present in green tea has the ability to block ...
... disease are alarming. According to a news release by McGill ... Canada and 8,500 deaths from the disease are expected every ... deaths, as reported by the Centers for Disease Control and ... and 16,000 deaths. ,However, here is some good ...
... the eyes can diagnose cerebral malaria in children, according ... complication where the Plasmodium falciparum parasite infects capillaries that ... to detect as patients can be unconscious and have ... ratio in cerebral malaria is 25-50 percent, reported science ...
Cached Medicine News:Health News:The Anti-HIV Properties Of Green Tea Uncovered 2
... Helmer PC1200 Platelet Incubators ... your laboratory counter top. These ... institution to have the security ... environment without taking up a ...
The PC4200i is the largest capacity platelet incubator available. It features a built-in agitator with a capacity of 396 random bags (132 apheresis)....
... rotators and agitators for continual ... set at 22C (71F) or ... (59F to 104F). Uniformity is ... bottom. Recorder is standard on ...
An enzyme-linked immuno-sorbent assay for the detection and quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Medicine Products: